Skip to main content
OpenTrials
Completed

NCT Number: NCT02576873

Long-term Outcome of End-stage Renal Disease Patients Treated With Hig-efficiency Hemodiafiltration

A retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in King Chulalongkorn Memorial Hospital between 2001-2013 to determine the survival rate as well as other long-term outcome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

End-stage Renal Disease Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Failure, Chronic Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

King Chulalongkorn Memorial Hospital

Pathumwan, Bangkok, 10330, Thailand

About this study

Growing evidences suggested the superiority of high-efficiency hemodiafiltration (HDF) which could provide both diffusion and convection in a single therapy compared with the conventional hemodialysis. However, the long-term, upto 10 years, outcome still limited. This retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in a single-center, King Chulalongkorn Memorial Hospital, between 2001-2013 to determine the survival rate as well as other long-term outcome

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 years or more
  • Be diagnosed end-stage renal disease for more than one year
  • Have been regularly received long-term hemodiafiltration for more than 6 months.

Exclusion criteria

  • Patients who received hemodiafiltration less than 6 months

Treatment and study plan

Hemodiafiltration

Other

Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies

Primary outcomes

  1. Survival rate

    Time frame: 10 years

    The Kaplan-Meier survival curve and mean survival time will be demonstrated for primary outcome.

Secondary outcomes

  1. Comparison of survival differences between patients who start renal replacement therapy with HDF and who switched from hemodialysis as well as between diabetic and non-diabetic patient.

    Time frame: 10 years

    Survival differences between groups will be evaluated with the Kaplan-Meier method and compared using the log-rank test. The comparative groups include:

    • Patient who start renal replacement therapy with HDF (incident cases) vs. who switched from hemodialysis (prevalence cases)
    • Diabetic vs. Non-diabetic patients

  2. Factors that associated with all-cause mortality

    Time frame: 10 years

    univariate and multivariate analysis the factors that might affected the long-term outcomes. The factors include dialytic parameters (spKt/Vurea, TAC urea), nutritional parameters (nPNA, albumin), inflammatory parameter (hsCRP), and biochemical parameters (BUN, Cr, Ca, Phosphate, iPTH, beta2-microglobulin, Hb, Ferritin, Transferrin saturation, Cholesterol, Triglyceride, HDL, and LDL)

Sponsors and collaborators

Lead sponsor

Chulalongkorn University

Other

Registry information

Official study title

Long-term Outcome of End-stage Renal Disease Patients Treated With High-efficiency Hemodiafiltration: a Historical Cohort of a Single-center in South East Asia

Important dates

Study start
2014
Primary completion
2015
Study completion
2016
First posted
Oct 15, 2015
Registry last updated
Jul 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.